Lung cancer is the deadliest cancer worldwide, exhibiting the highest incidence rate among all cancer types. Poor outcomes often characterize this cancer as it is commonly diagnosed in advanced stages due to its unspecific symptoms. After diagnosis, the therapeutic choice is a crucial stage that profoundly affects patients' survival. Treatment choices for lung cancer must be made carefully, acknowledging the histological type and genetic characteristics of the tumor. Non-small cell lung cancer, the most common and complex type, has a high mutational burden, making next-generation sequencing (NGS) essential for identifying specific mutations and guiding treatment. With several approved targeted therapies already available, this approach highlights the critical role of personalized medicine in lung cancer care. Despite the current therapeutic pipeline, research trying to develop new tailored drugs considering individual patient characteristics has evolved over the years. This article aims to outline the current therapeutic approach for each type of lung cancer and present the latest insights into emerging therapies, highlighting the role of personalized medicine in enhancing treatment outcomes and improving patients' quality of life.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3390/cancers17050725 | DOI Listing |
Clin Exp Immunol
March 2025
School of Medicine, Guizhou University, Guiyang 550025, China.
Introduction: Immunotherapy has rapidly become a primary treatment option for many lung cancer patients because of its success in treating this prevalent and deadly disease. However, the success of immunotherapy relies on overcoming the immunosuppressive tumour microenvironment, making remodelling this environment a potential strategy for lung cancer therapy. Research suggests that Toll-like receptor (TLR) agonists can impede tumour growth by promoting the conversion of tumour-associated macrophages into an M1-like state or enhancing dendritic cell development.
View Article and Find Full Text PDFFront Immunol
March 2025
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Lung cancer remains a leading cause of cancer-related deaths worldwide, necessitating innovative treatments. Tumor-associated macrophages (TAMs) are primary immunosuppressive effectors that foster tumor proliferation, angiogenesis, metastasis, and resistance to therapy. They are broadly categorized into proinflammatory M1 and tumor-promoting M2 phenotypes, with elevated M2 infiltration correlating with poor prognosis.
View Article and Find Full Text PDFInt J Chron Obstruct Pulmon Dis
March 2025
Department of General Medical, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Purpose: The miR-125a-5p has been reported influence the development of lung cancer, however, the link between it and chronic obstructive pulmonary disease (COPD) is still not well understood. Hence, this study was designed to investigate the molecular pathway by which miR-125a-5p related biomarkers were involved in COPD.
Patients And Methods: The differentially expressed genes (DEGs) and module genes related to COPD in GSE100153 were screened out by differential analysis and weighted gene co-expression network analysis, respectively.
J Diabetes Metab Disord
June 2025
Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular - Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Purpose: This comprehensive study examines the multifaceted relationship between vitamin D and cancer, synthesizing key scientific advancements and global research trends to guide future investigations and address critical gaps in the field.
Methods: Publications on vitamin D and cancer were retrieved from Scopus up to November 2024. English-language original and review articles were analyzed using Excel, VOSviewer, and Scimago Graphica, focusing on publication trends, citation impacts, and research themes.
J Inflamm Res
March 2025
Department of Thoracic Surgery, The second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213164, People's Republic of China.
Background: Studies have demonstrated that histone deacetylase 1 () enables cancer cells to evade killing mediated by cytotoxic T lymphocytes. However, there are no studies on the immunological aspects of in non-small cell lung cancer (NSCLC).
Methods: In this research, we used the Cancer Genome Atlas (TCGA) public database combined with tissue microarray (TMA) to investigate expression and prognosis in NSCLC.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!